Posts tagged ‘Bevacizumab’
Pieter Droppert will be attending the Association for Research in Vision & Ophthalmology (ARVO) annual meeting that starts in Fort Lauderdale this weekend.
This meeting offers insight into future ophthalmology new products & emerging vision research. What’s interesting about the ophthalmology market is it presents opportunities not only for innovative new drugs, but also medical devices.
Pieter on Biotech Strategy Blog has written a preview of what he expects to be hot at ARVO 2011 this year.
Eagerly awaited is Sunday’s special session on the National Eye Institute Comparison of Treatments Trials (CATT). Data will be presented comparing FDA approved ranibizumab (Lucentis®) to off-label bevacizumab (Avastin®) for the treatment of neovascular age-related macular degeneration (AMD).
The results, rumoured to show comparable efficacy, have tremendous commercial implications not only for Genentech, but other companies looking to enter the AMD market such as Regeneron/Bayer with aflibercept (VEGF-Trap).
An injection using bevacizumab off-label costs around $50, compared to $1950 for FDA approved ranibizumab.
You can read further news from ARVO on Biotech Strategy Blog.
Sally Church, PhD our oncology new products expert, is passionate about making a difference to the lives of patients with cancer. She channels her many talents and energies into helping pharma and biotech companies assess the best targets for their new products. It’s a job that requires science, marketing strategy and commercial awareness; a unique blend of skills.
Sally’s recent post on Pharma Strategy Blog entitled “Accelerated approval and cancer drugs” considers how best to bring new cancer drugs to market? Should promising oncology new products go from phase 2 clinical trials to market without the need for a large and expensive phase 3 registration study? If so, what happens when the data doesn’t pan out as happened with Roche/Genentech’s bevacizumab (Avastin) in breast cancer?
You can read more about Sally’s thoughts on Pharma Strategy Blog.
Published by Sally Church on Pharma Strategy Blog